Cardiovascular and gastrointestinal effects of COX-2 inhibitors …
2005年9月15日 · Studies of the COX-2 selective agents (COX-2 inhibitors) have demonstrated that they are associated with a significantly reduced risk for upper and lower gastrointestinal complications compared with conventional NSAIDs, although recent evidence indicates that this effect is partially or totally ameliorated in patients who are receiving concomita...
Risk of stroke associated with nonsteroidal anti-inflammatory drugs
Nonsteroidal anti-inflammatory drugs (NSAIDs), both cyclooxygenase (COX)-2-selective and nonselective agents, have been associated with the increased risk of adverse cardiovascular events. The majority of studies have focused on myocardial infarction as the primary cardiovascular outcome.
Cyclooxygenase-2 Inhibitors, Nonsteroidal Anti-inflammatory …
2008年11月1日 · Cyclooxygenase-2 (cox-2) inhibitors, also known as coxibs, were introduced with the promise that they would provide pain relief similar to that of traditional nonsteroidal anti-inflammatory drugs (NSAIDs) but would be better tolerated with …
Biological basis for the cardiovascular consequences of COX-2 ...
2006年1月1日 · Inhibitors selective for prostaglandin G/H synthase-2 (PGHS-2) (known colloquially as COX-2) were designed to minimize gastrointestinal complications of traditional NSAIDs — adverse effects attributed to suppression of COX-1–derived PGE 2 and prostacyclin (PGI 2). Evidence from 2 randomized controlled-outcome trials (RCTs) of 2 structurally ...
COX-2 inhibitors and gastroduodenal toxicity: Major clinical trials
One NSAID that selectively inhibits COX-2, celecoxib, is approved by the US Food and Drug Administration (FDA). Rofecoxib is a COX-2 inhibitor that was removed due to an increased risk of stroke and myocardial infarction with long-term use.
Cyclooxygenase-2 Inhibitors | Stroke - AHA/ASA Journals
2003年10月23日 · COX-2 inhibitors are as effective as aspirin and other “conventional” nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit both COX-1 and COX-2 activity, in relieving arthritic pain, yet they cause only half the number of adverse upper gastrointestinal events. 1,2 Central to their effectiveness is selective inhibition of the ...
Risks and benefits of COX-2 inhibitors - Oxford Academic
2007年1月25日 · The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs). We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.
Cyclooxygenase Inhibition and Cardiovascular Risk
2005年8月2日 · Both COX-1 and COX-2 are detectable in human atherosclerotic lesions 27,28; however, the specific effect of COX inhibition on lesion progression is currently controversial. Low-dose aspirin and selective COX-2 inhibitors have been shown to improve 29,30 or worsen 31 endothelial dysfunction in hypercholesterolemia and hypertension.
Cyclo-Oxygenase (COX) Inhibitors and Cardiovascular Risk: Are …
Rofecoxib and Celecoxib were the first selective COX-2 inhibitors to be marketed for their treatment of inflammatory conditions while minimising gastrointestinal disturbances attributed to COX-1 inhibition.
NSAIDs and coxibs: balancing of cardiovascular and ... - GOV.UK
2014年12月11日 · Gastrointestinal toxicity and cardiovascular toxicity are the two most important safety concerns for non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors (coxibs)....